Anti-Human CD73/NT5E Antibody (SAA0033)

Catalog No.

FHD46620

Species reactivity

Human

Host species

Human

Isotype

IgG1, Kappa

Clonality

Monoclonal

Conjugation

Unconjugated

Target

CD73, 5'-nucleotidase, NT5E, NT5, 5'-NT, Ecto-5'-nucleotidase, NTE

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P21589

Applications

FCM

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

SAA0033

Therapeutic potential of adenosine receptor modulators in cancer treatment., PMID:40530308

Ex vivo expansion of human disc chondrocytes from surgically removed disc tissue: Post-operative tissue stability., PMID:40501087

Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial., PMID:40450142

The cytotoxic effect of quercetin-induced apoptosis on lung metastatic cells from giant cell tumor of bone., PMID:40418557

Extracellular Inosine Induces Anergy in B Cells to Alleviate Autoimmune Hepatitis., PMID:40409684

Assessment of CD73 activity in breast cancer-derived small extracellular vesicles: application to monitoring of patients' responses to immunotherapy., PMID:40390761

Human naïve B cells show evidence of anergy and clonal redemption following vaccination., PMID:40368926

Interrogation of Structure-Activity Relationships in Charge Variants of Therapeutic IgG2s Enabled by Free-Flow Isoelectric Focusing Fractionation., PMID:40263152

Autophagy inhibition enhances antifibrotic potential of placental mesenchymal stem cells of fetal origin via regulating TGF-β1 mediated protein degradation of HGF., PMID:40258831

Morphological characteristics, extracellular vesicle structure and stem-like specificity of human follicular fluid cell subpopulation during osteodifferentiation., PMID:40253818

Phenotypic heterogeneity defines B cell responses to repeated SARS-CoV-2 exposures through vaccination and infection., PMID:40222009

CD73low B-cell phenotypes and distinct cytokine profiles in patients with active anti-Jo-1 antibody positive idiopathic inflammatory myopathies., PMID:40210261

Adenosine-generating CD39+ plasmablasts predispose to successful infliximab therapy in pediatric IBD., PMID:40199584

LuQi formula ameliorates pressure overload-induced heart failure by regulating macrophages and regulatory T cells., PMID:40118747

Development of CD73 Inhibitors in Tumor Immunotherapy and Opportunities in Imaging and Combination Therapy., PMID:40106690

Novel anti-CD73-IL-2v bispecific fusion protein augments antitumor immunity by alleviating immunosuppressive adenosine pathways in CD8+ T cells., PMID:40081940

Targeting Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer: Beyond PD-1/PD-L1 Monoclonal Antibodies., PMID:40075753

EZH2 coordinates memory B-cell programming and recall responses., PMID:40073167

Adapting radiation therapy to immunotherapy: Delineation and treatment planning of pre-operative immune-modulating breast iSBRT in 151 patients treated in the randomized phase II Neo-CheckRay trial., PMID:40057199

Exosomes in review: A new frontier in CAR-T cell therapies., PMID:40037165

Influence of surface texture on osteogenic differentiation of dental pulp stem cells: An in vitro study., PMID:40018713

Deep profiling of B cells responding to various pathogens uncovers compartments in IgG memory B cell and antibody-secreting lineages., PMID:39970201

Peripheral blood leukocyte signatures as biomarkers in relapsed ovarian cancer patients receiving combined anti-CD73/anti-PD-L1 immunotherapy in arm A of the NSGO-OV-UMB1/ENGOT-OV30 trial., PMID:39887612

Blocking the CD39/CD73 pathway synergizes with anti-CD20 bispecific antibody in nodal B-cell lymphoma., PMID:39884778

Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma., PMID:39875173

Pembrolizumab ± paricalcitol in metastatic pancreatic cancer postmaximal cytoreduction., PMID:39846984

Identification of B Cell Subpopulations with Pro- and Anti-Tumorigenic Properties in an Immunocompetent Mouse Model of Head and Neck Squamous Cell Carcinoma., PMID:39791721

An antibody cocktail targeting two different CD73 epitopes enhances enzyme inhibition and tumor control., PMID:39738003

Ectonucleotidase inhibitors: an updated patent review (2017-2023)., PMID:39460640

Dual immunostimulatory CD73 antibody-polymeric cytotoxic drug complex for triple negative breast cancer therapy., PMID:39341438

Human Ascaris infection is associated with higher frequencies of IL-10 producing B cells., PMID:39312581

Enhancing protein productivities in CHO cells through adenosine uptake modulation - Novel insights into cellular growth and productivity regulation., PMID:39151888

Differences in immunological profile in atopic dermatitis patients with and without dupilumab therapy., PMID:39148480

Isolation and characterization of stem cells from human exfoliated deciduous teeth., PMID:39132248

A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma., PMID:39106081

Mitigation of checkpoint inhibitor-induced autoimmune hemolytic anemia through modulation of purinergic signaling., PMID:39102659

PET imaging of colon cancer CD73 expression using cysteine site-specific 89Zr-labeled anti-CD73 antibody., PMID:39097625

The reduced frequency of CD39+CD73+ B cell subsets in SLE patients is correlated with disease activity., PMID:39094356

COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer., PMID:39048638

PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer., PMID:39023287

Targeting CD73 limits tumor progression and enhances anti-tumor activity of anti-PD-1 therapy in intrahepatic cholangiocarcinoma., PMID:39002018

NSGO-OV-UMB1/ENGOT-OV30: A phase II study of durvalumab in combination with the anti-CD73 monoclonal antibody Oleclumab in patients with relapsed ovarian cancer., PMID:38943691

Plasmodium vivax serological exposure markers: PvMSP1-42-induced humoral and memory B-cell response generates long-lived antibodies., PMID:38941356

Comparative Analysis of Primary Ovarian Cancer Cells and Established Cell Lines as a New Tool for Studies on Ovarian Cancer Cell Complexity., PMID:38791431

Comparative characteristics of the stem cells' number in the stromal vascular fraction of infrapatellar fat pad and subcutaneous fat tissue., PMID:38763383

Examining the Effects of Asiaticoside on Dental Pulp Stem Cell Viability and Proliferation: A Promising Approach to Root Canal Treatment., PMID:38514408

Regulatory T cell-derived exosome mediated macrophages polarization for osteogenic differentiation in fracture repair., PMID:38508525

Epitope Mapping of an Anti-Mouse CD39 Monoclonal Antibody Using PA Scanning and RIEDL Scanning., PMID:38507671

Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction., PMID:38483480

Faster clinical decisions in B-cell acute lymphoblastic leukaemia: A single flow cytometric 12-colour tube improves diagnosis and minimal residual disease follow-up., PMID:38432068

Document Download

Anti-Human CD73/NT5E Antibody (SAA0033).pdf